AML development on track
Q1 Ethics Committee approval cleared the way for Mendus and partner ALLG to start patient recruitment for the CADENCE trial in acute myeloid leukemia (AML) in Q2’24. In parallel, Mendus is building readiness for a pivotal-stage trial in AML supported by positive FDA feedback received during Q1. These key developments are supported by secured cash runway until Q3’25. We make minor adjustments to our estimates with no tangible impact to our DCF valuation of SEK 0.7.
Mendus
Mendus develops cancer immunotherapies with a focus on the prevention of tumor recurrence, the leading cause of cancer-related deaths globally. Indications include acute myeloid leukemia, ovarian cancer and soft tissue sarcomas. The company previously went by the name Immunicum and was renamed Mendus following the merger with the Dutch private company DCprime in 2021. Mendus today has its headquarters in Stockholm and its operational activities in Leiden, The Netherlands.
Read more on company pageKey Estimate Figures20.05
2023 | 24e | 25e | |
---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 |
growth-% | |||
EBIT (adj.) | -125.9 | -127.3 | -123.0 |
EBIT-% (adj.) | -1,259,210.00 % | -1,272,660.00 % | -1,229,630.00 % |
EPS (adj.) | -0.15 | -0.13 | -0.13 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |